文献速递淋巴瘤

PET/CT在结外边缘区淋巴瘤分期与治疗反应评估中的应用

PET/CT in the Staging and Treatment Response Assessment of Patients With Extranodal Marginal Zone Lymphoma.
PubMed 文献 · Am J Hematol · 2025-05-21

该研究回顾了152例结外边缘区淋巴瘤(EMZL)患者的190个结外病灶分期与反应评估PET/CT,发现79.5%的结外病灶(151/190)和76.7%的患者(117/152)呈FDG高摄取,中位SUVmax为4.5(IQR 2.5-6.9,范围0-26.8),提示EMZL常为FDG高摄取疾病,作者建议PET/CT应常规用于EMZL分期和反应评估。

要点

  • EMZL结外病灶中79.5%(151/190)呈FDG高摄取,患者中76.7%(117/152)呈FDG高摄取,中位SUVmax为4.5。
  • 涎腺、骨、肺、软组织、眼附属器和气道中超过90%的结外病灶显示FDG高摄取。
  • 22例有多个结外部位的患者中,18例(81.8%)所有部位FDG摄取一致。

核心结论

  • 本研究表明EMZL常为FDG高摄取疾病,作者认为PET/CT应常规用于EMZL患者的分期和反应评估。

研究设计与样本

  • 回顾性分析152例EMZL患者的190个结外病灶的分期和反应评估PET/CT,多结外部位患者每个部位独立计数。

主要发现

  • 190个结外病灶中151个(79.5%)呈FDG高摄取,152例患者中117例(76.7%)呈FDG高摄取,中位SUVmax为4.5(IQR 2.5-6.9,范围0-26.8)。
  • FDG高摄取比例超过90%的结外部位包括涎腺、骨、肺、软组织、眼附属器和气道,皮肤常为非FDG高摄取(93.8%)。
  • 22例有多个结外部位的患者中,18例(81.8%)所有部位FDG摄取一致。
  • 在可测量结外病灶大小>0.5 cm的病例中,淋巴瘤大小与SUVmax(r=0.20,p=0.019,n=142)、BP指数(r=0.34,p<0.001,n=124)和肝脏指数(r=0.36,p<0.001,n=124)呈显著Pearson相关。
  • 在FDG高摄取EMZL肿瘤中观察到治疗反应评估的精确度有所提高。

关键数值与推荐

  • 原文采用SUVmax≥2作为FDG高摄取的判定标准(原文注明该标准并非标准做法)。
  • 计算淋巴瘤SUVmax与纵隔血池(BP指数)及肝脏本底(肝脏指数)的比值。

临床怎么用

  • 作者认为PET/CT应常规用于EMZL患者的分期和反应评估。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

18Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard imaging modality in lymphoma. The 2014 Lugano classification considers extranodal marginal zone lymphoma (EMZL) a non-FDG-avid disease, recommending contrast-enhanced CT. We reassessed the utility of PET/CT for staging workup and response assessment of EMZL. We reviewed staging and response PET/CT of 190 EMZL sites from 152 patients. Each location was counted independently for patients with > 1 extranodal site. Although not standard, we considered FDG-avid disease if SUVmax was ≥ 2, and calculated ratios between lymphoma SUVmax and mediastinal blood pool (BP index) and liver background (liver index). FDG avidity was detected in 151 (79.5%) out of 190 extranodal sites (in 117 [76.7%] out of 152 patients), with a median SUVmax of 4.5 (IQR 2.5-6.9, range 0-26.8). Locations showing FDG avidity in > 90% of extranodal sites included salivary gland, bone, lung, soft tissue, ocular adnexa, and airways. Skin was commonly non-FDG avid (93.8%). Among 22 patients with > 1 extranodal location, there was concordant FDG avidity in all sites in 18 (81.8%) patients. Considering measurable extranodal disease size > 0.5 cm, we observed significant Pearson correlation coefficients (r) between lymphoma size and SUVmax (r = 0.20, p = 0.019, n = 142), BP index (r = 0.34, p < 0.001, n = 124), and liver index (r = 0.36, p < 0.001, n = 124). We also observed improved precision in response to treatment assessment in FDG-avid EMZL tumors. This study demonstrates that EMZL is commonly an FDG-avid disease, suggesting that PET/CT should be routinely used in the staging and response assessment workup of patients with EMZL.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Alderuccio JP, Kuker RA, Edelman Saul E, et al. PET/CT in the Staging and Treatment Response Assessment of Patients With Extranodal Marginal Zone Lymphoma. Am J Hematol. 2025. PMID: 40396679. doi:10.1002/ajh.27712

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。